Why the Market Punishes Some Companies With Female CEOs

 Why the Market Punishes Some Companies With Female CEOs

A new study explains why stocks sometimes fall. The incoming CEO for drugmaker GlaxoSmithKline is making history: Emma Walmsley, GSK’s chief of consumer health care, was recently tapped to become the first woman to head a top global pharmaceutical company, which will make her one of the highest-profile women in corporate Britain. Yet, while Walmsley’s appointment might be viewed as a victory for women entering the C-suite, this latest move might not encourage more women in corporate leadership to seek the spotlight actively.

There are a host of complex reasons why. When it comes to women as corporate leaders, our research shows that despite all the good reasons for trumpeting capable female leaders, corporations and their boards should also be aware of what can happen in the glare of the media spotlight surrounding the appointment of female CEOs.

Female CEOs

Research I conducted with Kevin Gaughan, a Ph.D. student at Northwestern University’s Kellogg School of Management, and Jason Pierce of the Universidad Adolfo Ibáñez looked at 94 appointments of female CEOs between 2000 and 2014—admittedly, a small universe compared to several thousand male CEOs named in the same timeframe, but more than in periods studied by previous researchers.

Specifically, we looked at the media attention received on the day of the CEO announcement, using a database covering several thousand unique media outlets. With all else held constant, the female CEO appointments drew three times more attention on the day of an announcement than when new male CEOs were announced.


One reason may be the rarity of such an event. Consider the 2016 Fortune 500 list. Only 21 companies are led by women, compared to 24 the year before; that translates to a mere 4.2% female representation among the leaders of America’s 500 biggest companies. Given the lack of top female executives, it might seem natural that when a corporation elevates a woman to become CEO, the inclination will generate as much buzz and attention as possible. After all, here is a company on the vanguard of promoting female leaders who, as some empirical research has shown, are equally or even better equipped to lead and manage companies than their male counterparts.

However, too much fanfare about a new female CEO can produce an unintended, negative consequence, as our study of market reaction suggests. When female CEO appointments generated a significant amount of media attention on the announcement day, stocks of those companies declined by an average of 2.5% in the immediate aftermath. But, when female CEO appointments received minimal attention, those companies saw a positive market reaction, with stocks rising an average of about 2%.

A compelling contrast emerges when male CEOs are named. Among those attracting a lot of media attention, there is an overall positive impact on the company’s stock—the exact opposite of what is experienced when a female CEO appointment is widely reported. When little attention was paid to a male CEO appointment, there was minimum impact on a company’s stock price.

So why is there a different reaction to the appointment of female CEOs? Contrary to prior research, we found that the reason may have little to do with overt gender bias among investors. Rather, we argue that the underlying cause is more likely a “bias of bias”—that is, investors anticipate the negative reactions of others. In other words, investors who may consider themselves fair-minded regarding gender assume that other investors are biased against female leaders. And the more media attention the appointment of a female CEO attracts, the more likely investors are to think about how others may react and subsequently sell the stock out of fear of others’ negative reactions.

This “bias of bias” is separate from any specific reasons why a particular CEO candidate, male or female, might be viewed positively or negatively. For example, according to media reports, Walmsley’s appointment to succeed Andrew Witty, who is scheduled to step down on March 31, 2017, may disappoint investors, including top shareholder Neil Woodford, who had wanted to see an outsider appointed to overhaul GSK. The company’s stock is currently down about 1% from late last week and more than 4% from the near-term high in August.

Dennis Bailey


Professional beer geek. Alcohol ninja. Social media scholar. Award-winning twitter fanatic. Writer. Basketball fan, mother of 2, audiophile, Saul Bass fan and communicator, collector, connector, creator. Producing at the sweet spot between simplicity and purpose to create strong, lasting and remarkable design. I'm a designer and this is my work.